RxDoctor Payments Data

John Liu, MD

Physical Medicine & Rehabilitation · Los Angeles, CANPI 1194739797

Payments from drug & device makers

$505in general payments, 2019–2025

Across 14 payments — averaging $36.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$146
  • AstraZeneca$97
  • Lilly USA, LLC$66
  • Aimmune Therapeutics, Inc.$48
  • Otsuka America Pharmaceutical, Inc.$29
  • Novartis$25
  • plus $94 from 5 others

What the payments were for

  • Food & beverage$505100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$505 in reported general payments places this provider in the 65th percentile of 830 physical medicine & rehabilitation providers in California.

See all physical medicine & rehabilitation providers in California

Medicare billing

Part B allowed, 2024
$1,027,112
Medicare patients
949
Services billed
9,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban368$118,796
JardianceEmpagliflozin90$32,898
JanuviaSitagliptin Phosphate41$15,643
Glucagon Emergency KitGlucagon48$13,735
Atorvastatin Calcium801$12,991
VelphoroSucroferric Oxyhydroxide12$11,028
MyrbetriqMirabegron42$10,879
XareltoRivaroxaban25$10,631
Pantoprazole Sodium314$10,097
BrilintaTicagrelor24$8,574
EntrestoSacubitril/Valsartan23$8,390
Glucagon Emergency KitGlucagon Hcl27$8,148
FarxigaDapagliflozin Propanediol17$7,570
TradjentaLinagliptin19$7,336
Memantine Hcl227$7,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Farxiga$97$16,14441 claims
NovartisEntresto$25$8,39023 claims
AbbVieLinzess$14$6,38811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 830 physical medicine & rehabilitation providers in California.

Other physical medicine & rehabilitation in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →